Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Bioavailability Study Design: Healthy Subjects Versus Patients
Hepatic Portal System
Bioavailability Study Design: Single Versus Multiple Dose Studies
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Aneurysm II: Clinical Manifestations and Diagnostic Studies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Mar 27, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
C S Landis1, M Ghabril2, V Rustgi3
1University of Washington, Seattle, WA, USA.
Overt hepatic encephalopathy (OHE) frequently recurs, causing significant healthcare burdens. Confusion and altered mental status are common symptoms, highlighting an unmet medical need despite rifaximin use.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: